Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virology

Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor

Philippe Bossi, Mireille Mouroux, Anne Yvon, François Bricaire, Henri Agut, Jean-Marie Huraux, Christine Katlama, Vincent Calvez
Philippe Bossi
Departments of Virology and
Infectious Diseases, Pitié-Salpêtrière Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mireille Mouroux
Departments of Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Yvon
Departments of Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
François Bricaire
Infectious Diseases, Pitié-Salpêtrière Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henri Agut
Departments of Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Marie Huraux
Departments of Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Katlama
Infectious Diseases, Pitié-Salpêtrière Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Calvez
Departments of Virology and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/JCM.37.9.2910-2912.1999
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

In order to analyze the impact of protease gene polymorphism on response to regimens containing a protease inhibitor, the entire protease coding domain from 58 human immunodeficiency virus type 1 (HIV-1)-infected patients who were protease inhibitor naive was sequenced before therapy was started. Plasma HIV-1 RNA levels were measured at baseline and at month 3 and month 6 after treatment. All patients were treated with a combination of two reverse transcriptase inhibitors and a protease inhibitor (saquinavir EOF [n = 28], ritonavir [n = 16], or indinavir [n = 14]). Before treatment, 30 different positions whose codons differed from the subtype B consensus sequence were observed. Major mutations associated with protease inhibitor resistance were not observed. No statistical correlation between the number of amino acid differences and the treatment efficacy at month 3 (−2.4 log) or month 6 (−2.7 log) was observed. At baseline, genotypic analysis of the HIV-1 protease gene of patients who have never received a protease inhibitor does not allow prediction of the efficacy of regimens containing a protease inhibitor.

Protease inhibitor regimens are associated with a decrease in plasma human immunodeficiency virus type 1 (HIV-1) RNA levels, an increase in CD4 lymphocytes, and prolonged survival of patients infected with HIV-1 (5). The appearance of drug-resistant virus under this treatment is possible. Protease inhibitor-resistant variants of HIV-1 have been described in vitro and in vivo, and numerous mutations in the protease have been determined (12, 13). Two categories of mutations have been reported: major mutations, usually located in the active site of the protease, and accessory mutations, located outside the active site. Both categories are usually required for high-level resistance (1, 2, 11, 25). However, the presence of numerous accessory mutations has been reported for patients who had not been previously exposed to a protease inhibitor (1, 8, 12, 13, 16, 21). In vitro, these accessory amino acid substitutions do not significantly alter the susceptibility of the protease inhibitors (1, 12, 16). However, during therapy, these amino acid substitutions have been described to have an influence on 50 and 90% inhibitory concentration increases (3, 14).

At baseline, the impact of these amino acid substitutions on response to treatment including a protease inhibitor is not known. At baseline, the influence of substitutions in the protease gene of patients naive for protease inhibitors on the virologic response to combinations including a protease inhibitor and two nucleoside reverse transcriptase inhibitors was analyzed.

(This work was presented in part at the 2nd International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24 to 27 June 1998, and at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September 1998.)

MATERIALS AND METHODS

At baseline, the sequence of the protease gene from 58 patients who were protease inhibitor naive was characterized. Among these patients, 12 had been treated previously with a combination of two nucleoside reverse transcriptase inhibitors. Plasma HIV-1 RNA levels were measured by Roche-Monitor assay (Roche Diagnostic Systems, Inc., Branchburg, N.J.), including the ultrasensitive assay, before introduction of the protease inhibitor and at 3 and 6 months afterward (lower limit of quantification, 20 copies/ml).

All patients were treated with two reverse transcriptase inhibitors and a protease inhibitor with usual daily dosages: 28 patients received saquinavir EOF (1,200 mg three times a day), 16 received ritonavir (600 mg twice a day), and 14 received indinavir (800 mg three times a day).

HIV-1 RNA was extracted from 200 μl of plasma by using the HCV specimen preparation kit (Roche Diagnostic Systems, Inc.), reverse transcribed to cDNA, and then directly amplified by nested PCR. The primers used for cDNA synthesis and PCR amplification and cycle conditions have been previously described (4). The entire protease coding domain from the 58 patients before introduction of the protease inhibitor was sequenced on an automated DNA sequencer (Applied Biosystems model 377) and compared to the HIV-1 clade B consensus sequence (15).

Statistical analyses were performed with nonparametric tests (Spearman’s rank correlation and Mann-Whitney U test).

RESULTS

Only one patient had a protease gene identical to the HIV-1 clade B consensus sequence. The protease sequences of the other 57 patients (98%) carried 1 to 9 amino acid differences from the consensus sequence. The median number of substitutions was 4: 34 patients harbored between 1 and 4 amino acid changes, and 23 had between 5 and 8 changes. A total of 30 positions differed from the consensus sequence, while the most frequent changes (prevalence, >20%) were located at positions 15, 35, 37, 41, 63, 77, and 93 (Table1). The substitution at position 63 was particularly frequent, as it was observed in 58% of the cases. The 63P substitution (44%) represented the most common amino acid change in the protease.

View this table:
  • View inline
  • View popup
Table 1.

Incidence of amino acid substitutions in the protease  (n = 58)

The major amino acid mutations associated with reduced sensitivity to protease inhibitors, at positions 30, 48, 50, 82, 84, and 90, were not observed.

The median plasma HIV-1 RNA levels were 47.479 copies/ml before introduction of the protease inhibitor, 162 copies/ml (−2.4 log10) at month 3, and 89 copies/ml (−2.7 log10) at month 6 after treatment. At months 3 and 6, 7 (12%) and 26 (45%) of 58 patients, respectively, achieved complete suppression of HIV-1 RNA in plasma (<20 copies/ml).

With Spearman’s rank correlation test, no statistical correlations between the number of protease amino acid substitutions and the decrease in HIV-1 RNA levels at months 3 and 6 were observed. Moreover, the presence of the 63P mutation did not influence the evolution of HIV-1 RNA levels.

The same results were observed when the tests were performed for each drug separately (saquinavir, ritonavir, and indinavir). Moreover, the numbers of amino acid substitutions were not significantly different between patients with complete therapeutic success (<20 copies/ml) and those without complete therapeutic success (>20 copies/ml) (Mann-Whitney U test).

DISCUSSION

No association between the number of amino acid substitutions present at baseline and the response to treatment including a protease inhibitor was observed.

Many mutations in the protease gene that cause inhibitor resistance have been described in vitro and in vivo (1-14, 16-26). The most common major mutations associated in vivo with resistance to indinavir and ritonavir are at position 82, those associated with resistance to nelfinavir are at position 30, those associated with resistance to saquinavir are at positions 48 and 90, and those associated with resistance to amprenavir are at position 50 (2, 4, 17, 20, 23). These major mutations usually occur first in the presence of a protease inhibitor. With the exception of the mutation at position 90, they are located in the active site of the protease. These mutations are associated with phenotypic resistance by reducing the binding affinity of the protease inhibitor to HIV protease (6). In this study, these kinds of mutations in the patient’s baseline protease sequence were not observed. However, many substitutions that have been described as accessory mutations, at positions 10, 33, 35, 36, 63, 71, and 77, were found in the protease from untreated subjects (12, 18, 20).

These accessory mutations are mainly located outside of the active site. Usually, molecular clones containing these changes do not reduce significantly the susceptibility to protease inhibitors in vitro. In vivo, rare cases of significant phenotypic change associated with these substitutions have been described (3). However, the combination of several accessory mutations with a major mutation is usually responsible for an increase in phenotypic resistance (1, 2, 11, 12, 25, 26).

Some observations of sequential early patient samplings have demonstrated that polymorphic changes precede the occurrence of resistance mutations, suggesting that polymorphic changes may serve as early markers of development of antiretroviral resistance (14). In this study, no statistical correlation between the number of substitutions in the protease gene from untreated patients at baseline and the response to treatment including a protease inhibitor was observed. Moreover, the number of accessory substitutions did not influence the rate of complete HIV-1 RNA viral load suppression (HIV-1 RNA level, <20 copies/ml).

At baseline, genotypic analysis of the HIV-1 protease gene from patients who have never received a protease inhibitor does not allow prediction of the efficacy of regimens containing a protease inhibitor.

FOOTNOTES

    • Received 4 January 1999.
    • Returned for modification 19 April 1999.
    • Accepted 14 June 1999.
  • Copyright © 1999 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Condra J. H.,
    2. Schleif W. A.,
    3. Blahy O. M.,
    4. Gabryelski L. J.,
    5. Graham D. J.,
    6. Quintero J. C.,
    7. Rhodes A.,
    8. Robbins H. L.,
    9. Roth E.,
    10. Shivaprakash M.
    In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors.Nature3741995569571
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Condra J. H.,
    2. Holder D. J.,
    3. Schleif W. A.,
    4. Blahy O. M.,
    5. Danovich R. M.,
    6. Gabryelski L. J.,
    7. Graham D. J.,
    8. Laird D.,
    9. Quintero J. C.,
    10. Rhodes A.,
    11. Robbins H. L.,
    12. Roth E.,
    13. Shivaprakash M.,
    14. Yang T.,
    15. Chodakewitz J. A.,
    16. Deutsch P. J.,
    17. Leavitt R. Y.,
    18. Massari F. E.,
    19. Mellors J. W.,
    20. Squires K. E.,
    21. Steigbigel R. T.,
    22. Teppler H.,
    23. Emini E. A.
    Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor.J. Virol.70199682708276
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Craig C.,
    2. Race E.,
    3. Sheldon J.,
    4. Whittaker L.,
    5. Gilbert S.,
    6. Moffatt A.,
    7. Rose S.,
    8. Dissanayeke S.,
    9. Chirn G.-W.,
    10. Duncan I. B.,
    11. Cammak N.
    HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.AIDS12199816111618
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.↵
    1. Eberle J.,
    2. Bechowsky B.,
    3. Rose D.,
    4. Hauser U.,
    5. von der Helm K.,
    6. Gurtler L.,
    7. Nitschko H.
    Resistance of HIV type 1 to proteinase inhibitor RO 31-8959.AIDS Res. Hum. Retroviruses111995671676
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    1. Flexner C.
    HIV-protease inhibitors.N. Engl. J. Med.338199812811292
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Gulnik S. V.,
    2. Suvorov L. I.,
    3. Liu B.,
    4. Yu B.,
    5. Anderson B.,
    6. Mitsuya H.,
    7. Erickson J. W.
    Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.Biochemistry34199592829287
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Ho D. D.,
    2. Toyoshima T.,
    3. Mo H.,
    4. Kempf D. J.,
    5. Norbeck D.,
    6. Chen C. M.,
    7. Wideburg N. E.,
    8. Burt S. K.,
    9. Erickson J. W.,
    10. Singh M. K.
    Characterization of human immunodeficiency virus type 1 variants with increased resistance to C2-symmetric protease inhibitor.J. Virol.68199420162020
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Jacobsen H.,
    2. Hanggi M.,
    3. Ott M.,
    4. Duncan I. B.,
    5. Owen S.,
    6. Andreoni M.,
    7. Vella S.,
    8. Mous J.
    In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies.J. Infect. Dis.173199613791387
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Jacobsen H.,
    2. Yasargil K.,
    3. Winslow D. L.,
    4. Craig J. C.,
    5. Krohn A.,
    6. Duncan I. B.,
    7. Mous J.
    Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.Virology2061995527534
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Kaplan A. H.,
    2. Michael S. F.,
    3. Wehbie R. S.,
    4. Knigge M. F.,
    5. Paul D. A.,
    6. Everitt L.,
    7. Kempf D. J.,
    8. Norbeck D. W.,
    9. Erickson J. W.,
    10. Swanstrom R.
    Selection of multiple HIV-1 variants with decreased sensitivity to an inhibitor of the viral protease.Proc. Natl. Acad. Sci. USA91199455975601
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. King R.,
    2. Garber S.,
    3. Winslow A.
    Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors.Antivir. Chem. Chemother.619958088
    OpenUrlCrossRef
  12. 12.↵
    1. Kozal M. J.,
    2. Shah N.,
    3. Shen N.,
    4. Yang R.,
    5. Fucini R.,
    6. Merigan T. C.,
    7. Richman D. D.,
    8. Morris D.,
    9. Hubbell E.,
    10. Chee M.,
    11. Gingeras T. R.
    Extensive polymorphisms observed in HIV-1 clade B protease gene high-density oligonucleotide arrays.Nat. Med.71996753759
    OpenUrlCrossRef
  13. 13.↵
    1. Lech W. J.,
    2. Wang G.,
    3. Yang Y. L.,
    4. Chee Y.,
    5. Dorman K.,
    6. McCrae D.,
    7. Lazzeroni L. C.,
    8. Erickson J. W.,
    9. Sinsheimer J. S.,
    10. Kaplan A. H.
    In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects.J. Virol.70199620382043
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Lloyd R. M. Jr.,
    2. Lacroix J.-M.,
    3. Hough L. M.,
    4. Houng J. T.,
    5. Feorino P. M.
    Polymorphic changes in HIV-1 pol as predictive molecular markers for resistance-associated mutations, abstr. I-76 Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1998 386 American Society for Microbiology Washington, D.C
  15. 15.↵
    Los Alamos National Laboratory Clade B consensus.Human retroviruses and AIDS.Myers G., Joseph S. F., Rabson A. B., Smith T. F.1987Los Alamos National LaboratoryLos Alamos, N.Mex
  16. 16.↵
    1. Markowitz M.,
    2. Mo H.,
    3. Kempf D. J.,
    4. Norbeck D. W.,
    5. Bhat T. N.,
    6. Erickson J. W.,
    7. Ho D. D.
    Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.J. Virol.691995701706
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Molla A.,
    2. Korneyeva M.,
    3. Gao Q.,
    4. Vasavanonda S.,
    5. Schipper P. J.,
    6. Mo H. M.,
    7. Markowitz M.,
    8. Chernyavskiy T.,
    9. Niu P.,
    10. Lyons N.,
    11. Hsu A.,
    12. Granneman G. R.,
    13. Ho D. D.,
    14. Boucher C. A.,
    15. Leonard J. M.,
    16. Norbeck D. W.,
    17. Kempf D. J.
    Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.Nat. Med.21996760766
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Molla A.,
    2. Granneman G.,
    3. Sun E.,
    4. Kempf D.
    Recent developments in HIV protease inhibitor therapy.Antivir. Res.391998123
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Otto M. J.,
    2. Garber S.,
    3. Winslow D. L.,
    4. Reid C. D.,
    5. Aldrich P.,
    6. Jadhav P. K.,
    7. Patterson C. E.,
    8. Hodge C. N.,
    9. Cheng Y. S.
    In vitro isolation and identification of human immunodeficiency virus (HIV) isolates with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.Proc. Natl. Acad. Sci. USA90199375437547
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Patick A. K.,
    2. Mo H.,
    3. Markowitz M.,
    4. Appelt K.,
    5. Wu B.,
    6. Musick L.,
    7. Kalish V.,
    8. Kaldor S.,
    9. Reich S.,
    10. Ho D.,
    11. Webber S.
    Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease.Antimicrob. Agents Chemother.401996292297
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Roberts N.,
    2. Craig J.,
    3. Sheldon J.
    Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice.AIDS121998453460
    OpenUrlCrossRefPubMedWeb of Science
  22. 22.↵
    1. Roberts N.
    Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors.AIDS9 (Suppl. 2)1995S27S32
    OpenUrlCrossRefWeb of Science
  23. 23.↵
    1. Schinazi R.,
    2. Larder B.,
    3. Mellors J.
    Mutations in retroviral genes associated with drug resistance.Int. Antivir. News51997114
    OpenUrl
  24. 24.↵
    1. Schmit J. C.,
    2. Ruiz L.,
    3. Clotet B.,
    4. Raventos A.,
    5. Tor J.,
    6. Leonard J.,
    7. Desmyter J.,
    8. De Clercq E.,
    9. Vandamme A. M.
    Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538).AIDS101996995999
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Tisdale M.,
    2. Myers R.,
    3. Maschera B.,
    4. Parry N.,
    5. Oliver N.,
    6. Blair E.
    Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.Antimicrob. Agents Chemother.39199517041710
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Vasudevachari M. B.,
    2. Zhang Y.-M.,
    3. Imamichi H.,
    4. Imamichi T.,
    5. Falloon J.,
    6. Salzman N. P.
    Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.Antimicrob. Agents Chemother.40199625352541
    OpenUrlAbstract/FREE Full Text
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor
Philippe Bossi, Mireille Mouroux, Anne Yvon, François Bricaire, Henri Agut, Jean-Marie Huraux, Christine Katlama, Vincent Calvez
Journal of Clinical Microbiology Sep 1999, 37 (9) 2910-2912; DOI: 10.1128/JCM.37.9.2910-2912.1999

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor
Philippe Bossi, Mireille Mouroux, Anne Yvon, François Bricaire, Henri Agut, Jean-Marie Huraux, Christine Katlama, Vincent Calvez
Journal of Clinical Microbiology Sep 1999, 37 (9) 2910-2912; DOI: 10.1128/JCM.37.9.2910-2912.1999
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Acquired Immunodeficiency Syndrome
HIV Protease
HIV Protease Inhibitors
HIV-1
Polymorphism, Genetic

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X